Lessons prom the PROVE-IT trial - Higher dose of potent statin better for high-risk patients CLEVELAND CLINIC JOURNAL OF MEDICINE Khush, K. K., Waters, D. 2004; 71 (8): 609-616


The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points.

View details for Web of Science ID 000223379600003

View details for PubMedID 15449756